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ABSTRACT 
 
Innate lymphoid cells (ILCs) are identified as novel population of hematopoietic cells which 
protect the body by coordinating the innate immune response against a wide range of threats 
including infections, tissue damages and homeostatic disturbances. ILCs, particularly ILC2 
cells, are found throughout the body including the brain. ILCs are morphologically similar to 
lymphocytes, express and release high levels of T-helper (Th)1, Th2 and Th17 cytokines but do 
not express classical cell-surface markers that are associated with other immune cell lineages.  
Three types of ILCs (ILC1, 2 & 3) have been reported depending upon the cytokines 
produced. ILC1 cells encompass natural killer (NK) cells and interferon (IFN)- releasing 
cells; ILC2 cells release the Th2 cytokines, IL-5, IL-9 and IL-13 in response to IL-25 and IL-
33; and ILC3 cells which release IL-17 and IL-22. ILC2 cells have been implicated in 
mucosal reactions occurring in animal models of allergic asthma and virus-induced lung 
disorders resulting in the regulation of airway remodeling and tissue homeostasis.  
There is evidence for increased ILC2 cell numbers in allergic responses in man but little is 
known about the role of ILCs in chronic obstructive pulmonary disease (COPD). Further 
understanding of the characteristics of ILCs such as their origin, location and phenotypes and 
function would help to clarify the role of these cells in the pathogenesis of various lung diseases. 
In this review we will focus on the role of ILC2 cells and consider their origin, function, 
location and possible role in the pathogenesis of the chronic inflammatory disorders such as 
asthma and COPD. 
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INTRODUCION 
 
Innate lymphoid cells (ILCs) are a newly identified 
population of immune cells which have been found in a 
variety of organs such as the gut, the lung and mucosal 
membranes.
1-4
 ILCs share many phenotypic, 
morphological, developmental and functional features 
with CD4+ T helper cells
1,3-6
 but do not express the 
characteristic adaptive immunity receptors/lymphoid 
lineage (Lin-) markers expressed on T-helper (Th) 
cells. ILCs are able to react to a wide array of stimuli 
5,7-9
 and play critical roles in lymphoid tissue formation 
and repair and in immune reactions against helminthic 
infections in several disease models. 
Although ILCs do not express Lin markers, they 
commonly express IL-2R (CD25), the IL-7 receptor α 
chain (IL-7Rα, CD127) and the common  chain 
(CD132) (Table 1).
10 
However, NK cells do not express 
CD127. ILCs are divided into 3 different classes 
depending upon their ability to synthesize and release 
Th1, Th2 and Th17 cytokines. Thus, type1 ILC (ILC1) 
cells produce interferon (IFN)-, type 2 ILC (ILC2) 
cells produce IL-5, IL-9 and IL-13 and type 3 ILC 
(ILC3) cells produce IL-17A and IL-22.
10
 Conventional 
and IFN--producing non-natural killer (NK) cells are 
the predominant examples of ILC1 and produce IFN 
under the control of the transcription factor T-bet as an 
innate counterpart to Th1 CD4+ cells.
10
 ILC3 cells, 
which include ILC17 and lymphoid tissue inducer cells 
(LTi cells) have been known for two decades 
5,11,12
 and 
have the ability to promote the formation of secondary 
lymphoid nodes in addition to Peyer’s patches during 
embryonic development.
5,10,11,13-16
 
The expression of IL-17A by ILC3 cells and their 
subsequent function is dependent upon Th17-associated 
transcription factors such as RORt and the aryl 
hydrocarbon receptor (AhR).
5,10,17-24
 RORt positive 
ILCs represent three subsets of cells namely LTi, 
ILC22 (IL-22 producing ILCs) and ILC17 (IL-17 
producing cells) (Table2). LTi cells are believed to be 
related to CD4+ cells 
5,25,26
 and produce cytokines such 
as TNF-5,27 and IL-17A.5,28 ILC3 cells which produce 
equal amounts of IL-17A and IL-22 are often 
considered a fourth ILC3 subset. There is debate as to 
whether these subsets represent distinct cell types or 
whether they are the result of local environmental 
stimuli on a single plastic cell type. In addition, a 
progenitor ILC population exists in blood which is 
capable of differentiating into RORt- or ROR-
dependent ILCs which are able to release IL-22 
(ILC22) or IL-13 (ILC2), respectively depending upon 
the local microenvironment.
1,28
 
ILC2 cells include nuocytes; natural helper cells 
(NH) and innate helper type 2 cells (Ih2) 
10,29-35
 which 
compose the third group of ILCs. These cells express 
CD127 (Lin-CD127+), T1-ST2, IL-17RB (a receptor 
for IL-25) and are dependent upon ROR and GATA3 
for their development (RORt-independent ILCs) 
10,28,32,36-39).
 These ILCs are derived from the common 
lymphoid progenitor cells in the bone marrow and 
require IL-25 and IL-33 for their development.
33,36,40 
 
Development of ILCs 
RORt-dependent ILCs are found in fetal liver in 
mice
5,41
 and after adoptive transfer are able to develop 
into several ILC lineages
5
 although this has not been 
formally confirmed for ILC3 cells. These ILC3 cells 
from fetal liver in mice are phenotypically similar to 
the common lymphoid precursor (CLP) cells found in 
adult bone marrow.
5
  
 
 
Table1. The ILC family 
Cell type Function Signature cytokine 
produced 
Major stimulating 
cytokines 
ILC1 cells 
(cytotoxic ILCs include NK and 
IFN-producing non-NK cells) 
Innate immunity against viral infections, 
tumor immunosurveillance 
IFN- IL-18, IL-12, IL-15 
ILC2 cells Innate immunity against extracellular 
parasites 
IL-5, IL-13 IL-25, IL-33 
ILC3 cells 
(RORt+ cells) 
Lymphoid tissue formation and repair, 
innate immunity against bacteria 
IL-17, IL-22 IL-1β, IL-23 
ILC: innate lymphoid cell, IFN: interferon, IL: interleukin, NK: natural killer, ROR: retinoic acid orphan receptor 
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Table 2. The retinoic acid orphan receptor (ROR)t+ ILC populations 
Subset Name Species Tissue distribution Function 
LTi cells LTi 
(fetal) 
Humans, mice Fetal lymphoid organs Lymphoid organ development 
LTi cells LTi-like 
(adult) 
Humans, mice Tonsil, adult mouse intestine, 
spleen 
Mucosal immunity, ILF 
formation, tissue modeling 
IL-22-producing ILCs NK22 Humans Tonsil, intestine, Peyer’s 
patches 
Epithelial homeostasis, 
intestinal immunity 
IL-22-producing ILCs NCR22 Mice Intestines, Peyer’s patches, 
spleen 
Epithelial homeostasis, 
intestinal immunity 
IL-22-producing ILCs NKR-LTi Mice Intestine Intestinal immunity 
IL-22-producing ILCs ILC22 Humans, mice Intestine, tonsil, Peyer’s patches Epithelial homeostasis, 
intestinal immunity 
IL-17 producing, IL-
17/IL-22 producing 
ILCs 
ILC17 Humans, mice Intestine, mouse spleen, tonsil Yeast immunity, intestinal 
pathology 
IL: interleukin, ILC: innate lymphoid cell, LTi: Lymphoid tissue-inducer cells, NCR: natural cytotoxicity receptors, NK: natural killer, NKR: NK cell 
receptor 
 
The expression of natural cytotoxicity receptors 
(NCRs) on ILC3 cells and NK cells in mouse and man 
initially suggested that ILC3 cells were a subpopulation 
of NK cells but recent evidence suggests that they are 
both derived from a common precursor cell following 
distinct developmental pathways.
5,42,43
 It is possible that 
the expression of RORt follows the commitment to the 
ILC3 lineage.  
IL-22 producing immature NK cells can 
differentiate into mature cytotoxic NK cells under the 
control of IL-1 46-49 suggesting a precursor role for 
immature NK cells in the induction of CD127+ IL-22 
producing ILCs. Further evidence for a developmental 
link between NK cells and LTi cells is that they both 
require the common cytokine receptor -chain (c; also 
known as IL-2R) and the transcriptional repressor 
inhibitor of DNA binding 2 (ID2) to develop. In 
contrast, ILC3 and LTi cell-like NKp46+ cells isolated 
from the gut express ROR indicating that they 
probably develop independently from NK cells.
44,45
 
In terms of ILC2 development, exposure to IL-7 is 
critical since ILC2 cell numbers are reduced in IL-7 
deficient mice.
5,30
 IL-2R is also present in ILC2 cells 
and in vitro evidence highlights key roles for IL-2 in 
ILC2 cell development, survival and expansion.
5
 It is 
likely, therefore, that ILC2 development is absolutely 
dependent upon the presence of at least two cytokines: 
IL-7 for ILC2 cell development and IL-25, IL-33 and 
indirectly IL-2 for the ILC2 recruitment, expansion and 
activity (Figure 1).
 5
 
 
Function of ILCs 
A) Mediator and Cytokine Release 
As described above, the three types of ILCs include 
NK cells (ILC1), ROR-(ILC2) and RORt-dependent 
ILCs (ILC3).
40,50
 Two latter types of ILCs do not 
express surface markers associated with the major 
hematopoietic lineages but they do express CD25 (IL-
2R); CD90 (Thy1); CD117 (c-Kit) and CD127 (IL-
7R).40 ILC2 cells express and produce ICOS 
(CD278); ST2 (IL-33R) and IL-17BR in response to 
IL-25 and IL-33 exposure.
51
 The same stimulus results 
in high levels of IL-5, IL-9 and IL-13 expression which 
is characteristic of these cells (Figure 2).
 10,40,51-54
 
In contrast, ILC3 cells in fetal lymph nodes (LN) 
and other tissues respond to IL-23 by secreting IL-17A 
and IL-22.
7,9,10,14,55
 ILC22 cells, despite being a 
member of the LTi group of ILCs, produce large 
amounts of IL-22, and to a lesser extent IL-26, in 
response to IL-23.
7,10,55-57
 However, it is evident that 
the local environment can also affect the cytokine 
profile produce by ILC22 cells. Thus, ILC22 cells also 
synthesize cytokines and chemokines such as IL-2; IL-
13, CXCL8, GM-CSF, and BAFF
5,8,58
 depending upon 
the local mucosal immune system and this is 
particularly evident in the intestine.
5,7,55,56,59,60
 The 
expression of inflammatory mediators and subsequent 
function by other ILC3 subsets also varies depending 
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upon context. Hence, whilst ILC17 cells have a critical 
role in the pathogenesis of intestinal diseases in mice 
where they co-produce IFN-, IL-22 and IL-17,10 ILC3 
are also involved in several aspects of tissue and 
mucosal functions such as organogenesis, tissue repair, 
mucosal immunity, homeostasis and pathology as well 
as modulating cancer progression in the absence of 
IFN- production.5 Deep immunophenotyping of 
human circulating blood ILC subsets indicated that 
patients with psoriasis have much greater numbers of 
IL-17A and IL-22 producing NKp44+ ILC3 cells than 
healthy individuals. The numbers of these cells was 
further increased in the skin of these patients 
suggesting a possible role for these cells in the 
pathogenesis of psoriasis.
61 
B) Lymphoid Organogenesis 
It is clear from their name that LTi cells are 
involved in the induction of lymphoid tissue 
organogenesis. This occurs mainly during fetal 
development even though LTi cells are present 
throughout life.
5,6
 The appearance of these Lin- 
RORt+ ILCs expressing high levels of CD117 and 
CD127 in human fetal lymph nodes occurs well before 
that of T cells.
5,6
 Mouse LTi cells express CD4 whereas 
this is not expressed on human LTi cells. However, 
lymphoid organogenesis is not affected in CD4 
knockout mice.
14, 62 
 
 
 
Figure 1. Simplified cartoon to indicate the drivers that regulate the production of the various innate lymphoid cell (ILC) 
subtypes. When exposed to interleukins (IL)-12, -15 or -18, ILC precursor (ILCP) cells are driven to produce ILC1 cells such 
as natural killer (NK) cells which produce interferon (IFN)-.  In contrast, exposure of ILCP cells to c cytokines such as  
IL-25 and IL-33 induces IL-5-, -9- and -13-producing ILC2 cells. The transcription factor retinoic acid receptor orphan 
receptor (ROR) is required to enable Th2 cytokine production. ILC3 cells are produced from RORt-containing ILCP cells 
under the control of IL-1 and IL-23.  Subpopulations of ILC3 cells are found which predominantly express IL-22 (ILC22), 
IL-17 (ILC17) or both IL-17 and TNF- (lymphoid tissue-inducer, LTi) cells. Some ILC3 cells produce equal amounts of 
both IL-17A and IL-22. 
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Figure 2. The role of ILC2 cells in the lung. IL-25 and IL-33 are produced by a diverse array of cell types including epithelial 
cells, alveolar macrophages (m) and dendritic cells (DC) in response to allergens, viruses and other parasitic stimuli e.g. 
helminthes within the lung. These cytokines activate type 2 innate lymphoid cells (ILC2) to produce large amounts of 
interleukin (IL)-5 and IL-13. This has profound effects in the lung causing the proliferation and survival of eosinophils (IL-
5), goblet cell differentiation and mucus production (IL-13), epithelial cell hyperproliferation (IL-13), airway smooth muscle 
hypercontractility and airway fibrosis (IL-13). Overall, this results in the impairment of airways hyperresponsiveness. Cross-
talk exists between ILC2 and other lymphocyte subsets including IL-22 producing ILC22 cells, Th2-cells and B-cells to 
enhance and maintain the interface between the innate and adaptive inflammatory/immune response in asthma.  
 
 
LTi cells are also required for the development of 
secondary lymphoid organs specifically lymph nodes 
and Peyer’s patches but not the spleen.5,6 In all cases of 
lymphoid organogenesis the key effector proteins are 
the TNF super family members lymphotoxins (LT)-α 
and -β and and TNF-α. Lymphotoxin binding to the 
LTR on stromal cells leads to the production of 
CXCL13 and of adhesion molecules providing a feed-
forward mechanism to recruit more LTi cells and the 
eventual formation of a lymphoid organ. 
RORt-positive ILC3-induced lymphoid 
organogenesis also occurs in the adult intestine.
63-66
 
ILC3 cells are important for the formation of small 
lymphocyte clusters in the gut, known as crypto 
patches, which contain ILCs, a small number of DCs 
but almost no T or B cells. 
63-66
 In addition, ILC3 cells 
also drive crypto patch transformation into isolated 
lymphoid follicles (ILFs) in response to microbial-
derived signals and high local IgA levels. These ILFs 
are important for the generation of IgA-producing 
plasma cells in the gut.
63-66
  
 
C) Tissue and Mucosal Repair 
The most important role of ILC3 cells with respect 
to tissue damage and repair is the reconstitution of the 
damaged spleen architecture resulting from infection by 
lymphocytic choriomeningitis virus (LCMV). This 
leads to a complete loss of B and T cell segregation and 
disrupts germinal center formation in adult human.
67
 
RORt positive ILCs show a capability of rebuilding in 
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these aspects.
67
 
IL-22 and IL-17 are absolutely essential in mucosal 
immunity, homeostasis and pathology.
5
 For example, 
IL-17-producing ILCs have been implicated in the 
pathology of intestinal infections and Crohn’s 
disease.
57,68
 RORt+ NKp46+ILCs are the major source 
of IL-22 in the mouse intestine and they reside mainly 
in intestinal mucosal tissue and palatine tonsils.
6, 55, 56, 
60, 69
 Cross-talk between these cells and epithelial cells, 
immune cells and the gut microflora is essential for gut 
homeostasis. For example, IL-22 can act directly on 
epithelial cells to induce the release of antimicrobial 
proteins and IL-23 release from DCs can modulate IL-
22 production from ILCs in an LTR-mediated 
manner.
70,71
 
In adults, the major sites of CD4+ ILC localization 
is within secondary lymphoid tissues particularly 
Peyer’s patches.25 NKp46+ ILCs also reside within the 
lamina properia of the intestine where they also 
produce large quantities of IL-22 and regulate mucosal 
homeostasis including mucus production.
69,72
 As 
described before, CD4
+
 RORt+ ILC3 cells are strongly 
associated with crypto patches, ILFs and the mesenteric 
lymph nodes in the murine intestine.
25,55,59,60
  
Human tonsil-derived ILC3s have similar 
characteristics to those from the murine gut. These cells 
also secrete IL-22 in response to IL-23 but this process 
requires a co-stimulus such as IL-2 or TLR activation. 
5
 
Interestingly, human ILC3 cells can produce IL-2 
raising the possibility of autocrine cell activation. IL-1 
can also modulate IL-22 production in conjunction with 
IL-2 and IL-15.
5
  
 
D) Role of ILCs in Cancer and Immunomodulation 
“The immune system plays a dual role in cancer” as 
Spits and Cupedo quote from de Visser et al.
5
 On one 
hand, the immune system may attack tumor cells 
leading to cancer regression whilst on the other hand, 
the same system can promote tumor growth through 
providing an immunosuppressive milieu within the 
tumor microenvironment.
5
 In a murine model of 
melanoma, RORt knockout mice did not show 
CCL21-mediated tumor growth due to a lack of 
CCR7
+
CD4
+
RORt+ cells. This effect is due to these 
cells facilitating the recruitment and differentiation of 
suppressive cells such as Treg cells.
73
 However, in 
other murine melanoma models, NK46
+
RORt+ cells 
had the opposite effect.
74
 Similarly, ILCs may have a 
dual effect in the regulation of inflammation depending 
upon the local conditions and cellular targets.
75
 
ILCs also modulate adaptive immune responses 
within the airway by controlling Th2
76-81
 and memory 
T cell 
82, 83
 survival. This process is mediated via direct 
interaction between ILCs and T-cells utilizing the 
expression of the T-cell costimulatory molecules OX40 
ligand and CD30 ligand on the ILC3 cell surface. The 
expression of these co-stimulatory molecules is 
regulated by the TNF family member TL1A and by IL-
7R signaling for OX40L and CD30L, respectively.
76-83
 
In addition, ILCs also drive the production of ILFs and 
IgA in the gut (see above). ILC3s activate latent 
Transforming growth factor beta 
Transforming growth factor beta (TGF-) and 
induce IgA synthesis via stimulation of matrix 
metalloproteinases. 
64
 Together this highlights the 
importance of RORt+ILCs in immune homeostasis in 
response to commensal bacteria in the gut 
64
 and 
potentially many other tissues.
75
 Interestingly, the 
circadian rhythm of blood eosinophilia may also be 
under ILC control.
84
 Long-lived tissue resident ILCs 
maintain blood eosinophil levels under the control of 
the vasoactive intestinal peptide (VIP). VIP is released 
in a circadian manner and stimulates ILCs to increase 
IL-5 expression. 
 
E) Role of ILCs in Respiratory Systems 
As described earlier, ILCs represent distinct 
immune cell populations which perform key immune 
functions throughout the body. They are classified into 
three categories depending upon their developmental 
origins: Type 1 cells are represented by IFN--
producing NK cells, Type 2 cells are ROR+ Th2 
cytokine producing cells and Type 3 cells are RORt+ 
cells that produce IL-17A, IL-22 and TNF- depending 
upon the subset.
1-4
 Many allergic or noxious challenges 
to the respiratory system may trigger airway epithelial 
cells to release cytokines such as IL-25 and IL-33.
1,29,85
 
These cytokines, in turn, can act on ILC2 or ILC-
precursor cells to express Th2 cytokines such as IL-5 
and IL-13
1,29,85
 rather than IL-22, IL-17A or IFN-.31,86 
Non-lineage-expressing (Lin-) cells which express 
CD25 and CD127 markers are found in the lung 
parenchyma and bronchoalveolar lavage (BAL) fluid of 
subjects undergoing lung transplantation.
1,39,86,87
 These 
cells are analogous to murine ILCs and have previously 
been found in gut-associated lymphoid tissue (GALT), 
fat-associated lymphoid clusters (FALC) and in the 
spleen.
29, 30, 32
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Animal models, and to a much lesser extent studies 
in human tissue, have begun to reveal the critical role 
of ILC2 cells in the respiratory tract during asthma and 
chronic rhino-sinusitis, in protease-allergen-induced 
airway inflammation and in parasitic and fungal 
infections.
10, 28-32, 39, 50, 53
 These challenges result in the 
increased production of Th2 cytokines which is 
characteristic of the pathogenesis of these disorders.
10, 
28-32, 39, 50, 53, 88
 Not surprisingly, the most common ILC 
reported in the human respiratory tract are RORt-
independent ILC2 cells which, as detailed above, 
produce Th2 cytokines in response to IL-25, IL-33 and 
IL-2 exposure.
28
 The local airway environment may 
affect the expression of ILC2 cell surface markers such 
as CD117 and CD45 which may have functional 
consequences.
89
  
ILC2 cells represent less than 1% of all CD45
+
 cells 
in tissues and only 0.01-0.03% of cells in circulating 
blood of healthy people. However, cell numbers are 
increased in human lung, intestine and palatine tonsils.
5
 
Table 3 describes the distribution and function of ILC2 
cell in mouse and man. Studies have also established 
that ILC2 cells from human peripheral blood have a 
more plastic phenotype regarding their IL-22 
production compared to tissue-localized ILC2 cells 
with some expressing low levels of, or even no, IL-
22.
28
  
ILC2 cells accumulate in the lung following H1N1 
influenza virus infection. ILC2 cells do not directly 
affect immunity against the virus since depletion of 
ILC2 after H1N1 infection did not affect viral load. 
Rather, ILC2 cells are likely to play a major role in 
maintaining the epithelial cell barrier since ILC2 
depletion had profound effects on epithelial cell 
damage following viral infection.
90
 This effect was not 
mediated by IL-22 but by the release of amphiregulin, a 
member of the epidermal growth factor (EGF) family, 
from ILC2 cells.
33
 IL-22 may also be important in 
epithelial cell damage/repair processes in ovalbumin-
challenge models 
33
 through promoting epithelial cell 
proliferation following IL-13 release from ILC2 cells.
39, 
91-94 
 
F) ILCs in Pathogenesis of Asthma 
The possible role of ILC2 in the pathogenesis of 
human allergic asthma recently has been appreciated.
95
 
Allergic asthma is a chronic inflammatory condition of 
the airways which is characterized by airway 
hyperreactivity (AHR), bronchoconstriction, increased 
mucus secretion and limited airflow. This is usually 
associated with elevated serum IgE, eosinophilia and 
goblet cell hyperplasia in those patients with a clear 
allergic disease with heightened expression of Th2 
cytokines.
52, 96-103
 ILC2 cells identified in the human 
lung resemble their intestinal counterparts as they 
express ICOS, ST2, CD25 and CD44 on the cell 
surface.
28, 33, 40, 102, 103
  
Both NK cells and ILC2s are found asthmatic and 
healthy volunteer lung and peripheral blood. Severe 
asthma patients had evidence for activated NK cells 
which were able to promote eosinophil apoptosis.104 
 
Table 3. ILC2 cell populations/subtypes 
Cell Species Tissue distribution Function/pathology 
Natural helper cells 
(NH) 
Wild type mouse Fat associated lymphoid 
tissue, lung 
Nematode expulsion, airway pathology/tissue 
repair following viral infection 
Nuocytes IL-13-GFP reporter 
mouse 
Intestine, mesenteric lymph 
nodes 
Nematode expulsion 
Innate helper 2 cells 
(ih2) 
IL-13-GFP and IL-
14-GFP reporter 
mice 
Broad, spleen, liver, 
mesenteries 
Nematode expulsion 
Multi-potent progenitor 
population (MPP) 2 
IL-25 knock out 
mice 
Gut-associated lymphoid 
tissue 
Promotes Th2 cytokine responses in response 
to IL-25 and confers protective immunity to 
helminth infection 
ILC2 Humans Fetal and adult gut and 
lung, adult peripheral blood 
Chronic rhinosinusitis 
IL: interleukin, ILC: innate lymphoid cell, GFP: green fluorescent protein. 
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In addition, the combination of mast cell-derived 
prostaglandin D2 and epithelial cell-derived IL-25 and 
IL-33 resulted in enhanced ILC2 production of IL-13. 
Since the expression of lipoxin A4 is reduced in severe 
asthma, ILC activation may not be regulated in these 
patients. 
In animal models of allergic asthma, IL-13 release 
from ILC2 cells has been shown to be an essential 
director of AHR, mucus hyper secretion and 
inflammation.
39, 40, 50, 52, 98,105-107
 These studies indicate 
that activation of ILC2 occurs not only following 
intranasal IL-25 or IL-33, as the main stimulators of 
ILCs, but also following the exposure to fungal 
aeroallergens such as Alternariaalternata.
31, 35, 39, 40, 50, 
52, 87, 108
 Alternaria exposure, in turn, results in an 
increase in the expression of IL-5, IL-13, IL-6, IL-9, 
and IL-10.
29, 35, 108
 IL-33 is also released from alveolar 
macrophages, (DCs) and type 2 pneumocytes following 
infection or exposure to allergens 
31, 87, 103, 109-112
 and 
would be able to activate ILC2 cells.
1, 31, 52
 In addition, 
IL-25 may also be released from basophils and 
eosinophils following allergen challenge in animal 
models of asthma.
113, 114
 Furthermore, infection by 
parasites and by viruses also leads to the production of 
IL-5 and IL-13 from ILC2 cells.
115, 116
 In all cases the 
level of Th2 cytokines released from ILC2 cells into 
the lungs is at least similar to that released from Th2 
cells and is often much greater than the Th2-dependent 
release.
95
 In contrast, ILC2 cells produce little IL-4 and 
most IL-4 is derived from Th2 cells in animal models 
of asthma.
50, 98
  
Chronic rhinosinusitis is an inflammatory disease 
associated with high levels of IL-13, IgE, eosinophils 
and the presence of nasal polyps. Human ILC2 express 
a prostaglandin D2 receptor named chemoattractant 
receptor expressed on Th2 cells (CRTH2) and elevated 
numbers of CRTH2
+
 ILCs were found in nasal polyps 
of chronic rhinosinusitis patients compared to control 
subjects.
28
 The authors did not measure IL-25 or IL-33 
levels in the polyps. In addition, the utility of anti-IL-
13 treatment in patients with severe asthma.
117
 
New therapeutic strategies targeting ILCs may 
therefore be important for allergic airway diseases.
28
 
In addition to ILC2 cells, IL-22-producing ILCs 
have also been recently found in the lung parenchyma 
of mouse models of allergic asthma.
118, 119
 As described 
above, ILC22 cells play important roles in tissue repair 
and epithelial integrity in the respiratory tract and may, 
as reported for IL-17A, also have a protective effect on 
inflammation through effects on DCs.
120-122
 
 
G) ILCs in COPD 
Chronic obstructive pulmonary disease (COPD) is 
characterized by a chronic inflammation of the airways 
triggered by inhaled noxious particles and gases, 
mostly cigarette smoke (CS), leading to progressive 
bronchitis and/or emphysema that causes an 
irreversible airflow limitation of the lungs.
123-125
 
COPD-induced lung inflammation involves 
neutrophils, CD4
+
 and CD8
+
 lymphocytes, 
macrophages and DCs. Although eosinophils are not 
usually present in stable disease, increased numbers 
have been observed during acute exacerbations of 
COPD (AECOPD) in a large (30%) subgroup of 
patients.
126
 Liesker et al.
127
 demonstrated that sputum 
eosinophil numbers are significantly increased during 
AECOPD which coincides with a significant 30-fold 
increase in IL-13 mRNA levels.
127, 128
 At present, the 
trigger and cellular source for IL-13 gene expression in 
AECOPD is unknown. Although Th2 lymphocytes 
express IL-13, these cells are not considered to be 
implicated in COPD pathogenesis. It is tempting to 
speculate that ILC2 cells may play a role in this 
scenario.  
Interestingly, respiratory viral infection, important 
triggers of AECOPD, induces the accumulation of ILCs 
in lung tissue of mice.
129
 Depletion of ILCs with anti-
CD90.2 antibody strongly reduced BAL eosinophil 
numbers and IL-5 and IL-13 mRNA expression in lung 
tissue upon respiratory viral infection.
130
 Since IL- 33 is 
a critical trigger for ILC activation after respiratory 
viral infection in mice, it is tempting to speculate that 
IL-33 release and subsequent ILC2 activation results in 
the enhanced IL-5/IL-13 expression and eosinophilia 
seen in AECOPD.  
IL-33 is a chromatin-associated nuclear cytokine 
that is abundant in epithelial and endothelial cells and 
is considered not to be actively secreted but only 
released upon cellular damage or necrotic cell death.
131
 
NALP3 inflammasome-mediated activation of caspase-
1 activity results in the release of an inactive form of 
IL-33 in contrast to the production of active forms of 
IL-1β and IL-18.131 Interestingly, full-length IL-33 is 
processed into a mature form with superior biological 
activity (10-fold higher than full-length IL-33) by 
neutrophil elastase and cathepsin G.
132
 Neutrophilic 
S. M. Marashian, et al. 
354/ Iran J Allergy Asthma Immunol, Summer 2015                            Vol. 14, No. 4, August 2015 
Published by Tehran University of Medical Sciences (http://ijaai.tums.ac.ir) 
airway inflammation is a characteristic of COPD 
patients and neutrophil elastase and cathepsin G levels 
are increased in sputum from AECOPD patients.
133
 
Therefore, neutrophil elastase and cathepsin may 
induce maturation of IL-33 released from necrotic 
epithelial or endothelial cells into a molecule with 
superior biological activity. 
ILCs may not only play a role in AECOPD but also 
in the early development of COPD
129
 since cigarette 
smoke extract (CSE) switches airway epithelial cell 
apoptosis into necrosis.
134
 Furthermore, CSE-induced 
necrosis of airway epithelial cells was associated with 
the release of various damage-associated molecular 
patterns (DAMPs).
135
 In a mouse model of cigarette 
smoke-induced neutrophilic airway inflammation, a 
model of COPD inflammation, we have demonstrated 
that the inflammation is preceded by epithelial 
sloughing and the presence of DAMPs in BAL fluid, 
indicating necrosis of airway epithelial cells.
135
 
Although we have not measured the levels of IL-33 in 
this model, it is tempting to speculate that ILC17 and 
ILC2 cells have been activated since serum IL-17 and 
BAL IL-5 levels were significantly increased.  
These increases in IL-5 and IL-17 levels occur too 
early to be produced by differentiated Th17 cells and 
point to a role for ILC2 and ILC17 cells. However, a 
role for other IL-17-producing innate immune cells or 
even epithelial cells
136
 cannot be excluded. 
Interestingly, there is evidence that IL-17 is produced 
by innate immune cells in COPD patients. Chang et 
al.
31
 demonstrated that 80% of the IL17
+
 cells in the 
airways of COPD patients were not CD4
+
 or CD8
+
 
lymphocytes.  
 
Future Perspectives on the Roles of ILCs in Lung 
Disease 
Although the role of ILC cells in animal models of 
asthma and COPD are clear, there is little evidence in 
human disease. It is important that future studies 
examine the expression of these cells in human 
airways, sputum and bronchoalveolar lavage for 
example and determine how they link with the adaptive 
immune system within the human lung. It is also 
unclear what effects anti-inflammatory agents such as 
steroids have on the number and function co these cells.  
In addition, it is unclear whether ILC subsets 
represent truly distinct populations of cells or merely 
reflect different states of a plastic precursor cell 
exposed to a specific local microenvironment. More 
sophisticated analysis of the gene expression and 
regulatory patterns are needed in these cells. The 
critical signaling pathways or proteins that control cell-
cell interactions are also areas that need to be 
elucidated. This is even more evident in the case of 
human airways disease where these may provide 
important novel therapeutic targets particularly in 
relation to viral and bacterial infections and the 
maintenance of an intact epithelial barrier. 
The discovery of the role of these cells in mouse 
models of asthma and COPD has opened up an exciting 
era of research which may explain the anomalies 
reported to date regarding the presence of Th2 cells and 
markers in asthma for example. It is hoped that further 
understanding of the functions of these cells in human 
disease will lead to novel anti-inflammatory approaches 
in severe asthma and COPD where there is a major 
unmet clinical need. 
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